| 8.84 -0.73 (-7.63%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 13.39 |
1-year : | 15.44 |
| Resists | First : | 11.47 |
Second : | 13.22 |
| Pivot price | 10.71 |
|||
| Supports | First : | 8.64 |
Second : | 7.18 |
| MAs | MA(5) : | 9.69 |
MA(20) : | 11.21 |
| MA(100) : | 9.73  |
MA(250) : | 15.07 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 2.3 |
D(3) : | 3.9 |
| RSI | RSI(14): 27.1 |
|||
| 52-week | High : | 34.7 | Low : | 6.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RXST ] has closed above bottom band by 1.5%. Bollinger Bands are 74.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.64 - 9.71 | 9.71 - 9.76 |
| Low: | 8.48 - 8.56 | 8.56 - 8.63 |
| Close: | 8.72 - 8.84 | 8.84 - 8.93 |
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Tue, 06 Jan 2026
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Investors to Inquire about Securities Investigation - ACCESS Newswire
Fri, 02 Jan 2026
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference - Sahm
Thu, 01 Jan 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST - PR Newswire
Tue, 23 Dec 2025
RxSight down on CFO transition (RXST:NASDAQ) - Seeking Alpha
Mon, 22 Dec 2025
RxSight, Inc. Announces Transition of Chief Financial Officer Shelley Thunen | RXST Stock News - Quiver Quantitative
Fri, 12 Dec 2025
RxSight, Inc.'s (NASDAQ:RXST) 28% Price Boost Is Out Of Tune With Revenues - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 41 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 81.6 (%) |
| Shares Short | 4,420 (K) |
| Shares Short P.Month | 4,390 (K) |
| EPS | -0.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.71 |
| Profit Margin | -25.2 % |
| Operating Margin | -40.2 % |
| Return on Assets (ttm) | -9.2 % |
| Return on Equity (ttm) | -13 % |
| Qtrly Rev. Growth | -14.2 % |
| Gross Profit (p.s.) | 2.59 |
| Sales Per Share | 3.45 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -10.05 |
| PEG Ratio | 0 |
| Price to Book value | 1.31 |
| Price to Sales | 2.55 |
| Price to Cash Flow | -19.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|